Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MaxFe is a prescription-strength oral multivitamin and multimineral dietary supplement marketed by Seyer Pharmatec, primarily used for the management of iron deficiency and iron-deficiency anemia. It is frequently utilized as supportive care in cancer patients to manage treatment-related anemia and is also indicated for folate-deficiency anemia. The formulation is comprehensive, containing 160 mg of elemental iron alongside essential erythropoietic cofactors including folic acid (vitamin B9), cyanocobalamin (vitamin B12), and biotin (vitamin B7). To optimize therapeutic outcomes, the supplement includes ascorbic acid (vitamin C) to enhance intestinal iron absorption, as well as magnesium and zinc. Notably, MaxFe incorporates docusate, a stool softener, to mitigate constipation, which is a common gastrointestinal side effect of high-dose oral iron therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MaxFe.